OUP user menu

Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease

Crystal M Rasnake , Paula R Trumbo , Therese M Heinonen
DOI: http://dx.doi.org/10.1111/j.1753-4887.2007.00010.x 76-81 First published online: 1 February 2008

Abstract

This article reviews surrogate endpoints and emerging biomarkers that were discussed at the annual “Cardiovascular Biomarkers and Surrogate Endpoints” symposium cosponsored by the US Food and Drug Administration (FDA) and the Montreal Heart Institute. The FDA's Center for Food Safety and Applied Nutrition (CFSAN) uses surrogate endpoints in its scientific review of a substance/disease relationship for a health claim. CFSAN currently recognizes three validated surrogate endpoints: blood pressure, blood total cholesterol, and blood low-density lipoprotein (LDL) concentration in its review of a health claim for cardiovascular disease (CVD). Numerous potential surrogate endpoints of CVD are being evaluated as the pathophysiology of heart disease is becoming better understood. However, these emerging biomarkers need to be validated as surrogate endpoints before they are used by CFSAN in the evaluation of a CVD health claim.

  • biomarkers
  • cardiovascular disease
  • health claims
  • surrogate endpoint
View Full Text

Log in through your institution